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Abstract
Background:  Congenital lactase deficiency (CLD) is a severe gastrointestinal disorder of
newborns. The diagnosis is challenging and based on clinical symptoms and low lactase activity in
intestinal biopsy specimens. The disease is enriched in Finland but is also present in other parts of
the world. Mutations encoding the lactase (LCT) gene have recently been shown to underlie CLD.
The purpose of this study was to identify new mutations underlying CLD in patients with different
ethnic origins, and to increase awareness of this disease so that the patients could be sought out
and treated correctly.
Methods: Disaccharidase activities in intestinal biopsy specimens were assayed and the coding
region of LCT was sequenced from five patients from Europe with clinical features compatible with
CLD. In the analysis and prediction of mutations the following programs: ClustalW, Blosum62,
PolyPhen, SIFT and Panther PSEC were used.
Results: Four novel mutations in the LCT gene were identified. A single nucleotide substitution
leading to an amino acid change S688P in exon 7 and E1612X in exon 12 were present in a patient
of Italian origin. Five base deletion V565fsX567 leading to a stop codon in exon 6 was found in one
and a substitution R1587H in exon 12 from another Finnish patient. Both Finnish patients were
heterozygous for the Finnish founder mutation Y1390X. The previously reported mutation G1363S
was found in a homozygous state in two siblings of Turkish origin.
Conclusion: This is the first report of CLD mutations in patients living outside Finland. It seems
that disease is more common than previously thought. All mutations in the LCT gene lead to a
similar phenotype despite the location and/or type of mutation.
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Background
Congenital lactase deficiency (CLD [MIM 223000]) is a
severe form of lactase deficiency in which lactase activity
is very low or absent in the intestinal wall from birth [1,2].
The main symptoms are watery diarrhoea in the first days
of life after ingestion of lactose that leads to severe dehy-
dration and loss of weight gain if untreated. Symptoms
can be avoided and patients can have normal growth and
development by changing to a lactose-free diet. The activ-
ities of other disaccharidases and the histological structure
of the epithelium of the small intestine are normal [3,4].
Most CLD cases have been found in Finland where the
disorder is enriched due to a founder effect and genetic
drift [2,5]. This is in contrast to adult-type hypolactasia
(where lactase activity declines after weaning) that is com-
mon all over the world [6-8]. Since the reports by Holzel
et al. [1,9], there has been a lack of published data about
CLD in countries other than Finland.
Mutations in the lactase gene (LCT [GeneID: 3938]) have
recently been identified to underlie CLD in Finnish fami-
lies [10]. Of the five mutations, Y1390X was the founder
mutation present in 90% of the disease alleles. In addi-
tion, four other family specific mutations, S1666fsX1722,
S218fsX224, G1363S and Q268H were identified in the
Finnish population. However, no mutations have been
found outside Finland. In order to further characterize the
spectrum of mutations we have sequenced the coding
region and splice sites of the LCT gene in five patients orig-
inating from Italy, Finland and Turkey, with clinical fea-
tures compatible with CLD.
Methods
Case 1
A male infant of unrelated, healthy parents of Italian ori-
gin with unremarkable family histories was born at term
after an uneventful pregnancy with a birth weight of 3180
g. At the age of 10 days, he was admitted to the neonatol-
ogy intensive care unit because of metabolic acidosis. On
admission, his weight was 2774 g and he showed watery
diarrhoea on breast feeding. Clinitest®  on stools was
strongly positive, reducing sugars higher than 20 g/dl and
stool pH was low (pH5). Diarrhoea promptly stopped
after starting parenteral rehydration and stopping oral
feeding. After seven days a further attempt to breast-feed
this baby, led again to osmotic diarrhoea and weight loss.
Stools quickly became normal after putting the child on a
lactose-free, cow's milk protein-based formula, where the
child remained well. At age 3 months his weight was 5890
g (50th centile). An oral lactose tolerance test with 2 g/kg
of lactose showed no increase in glucose blood levels
within 120 minutes and was followed by watery diarrhoea
within a few hours. His faeces were positive for reducing
sugars, which was shown to be lactose by high-perform-
ance liquid chromatography (HPLC). The child was dis-
charged on a lactose-free, soy protein-based formula and
remained well on a lactose-free diet. At age 12 months, his
weight was 9860 g (50th centile). A small intestinal biopsy
specimen was taken using the Watson capsule. His small
intestinal morphology was normal on standard histologi-
cal examination, as far as the villous height, crypt depth
and intraepithelial lymphocyte count were concerned.
Lactase activity measured by the Dahlqvist method [11] at
the Scientific Laboratory of the Hospital for Children and
Adolescents, University of Helsinki was very low 4 U/g/
protein, while values of other disaccharidases were nor-
mal (data not shown). At the last follow-up visit (age 15
months) this baby was perfectly healthy on a lactose-free
diet.
Case 2
The Finnish patient was the first child of the healthy par-
ents. Because of pre-eclampsia and intrauterine growth
failure, a Caesarean section was performed after 35 weeks
of gestation. After birth, oral and intravenous nutrition
were started. On breast milk, the infant needed high
amounts of iv glucose, and had watery stools. When put
on hydrolyzed, lactose free formula, the diarrhoea
stopped and iv nutrition could be stopped at the age of 2
weeks. At 4 weeks of age, he was transferred to breast milk
and sent home. After one week on breast milk at home, he
was taken back to the hospital. Loss of weight and severe
acidosis was found in the patient. After iv fluid therapy, he
was put back on the hydrolyzed formula and based on the
disappearance of symptoms, he was suspected to have
congenital lactase deficiency (CLD). At the age of 6
months, a jejunal specimen for morphological studies,
and disaccharidase activity measurements was obtained
by a suction biopsy device [11]. The morphology of his
duodenum was quite normal; the activity for maltase and
sucrase were normal (data not shown). Lactase activity
was 8 U and the lactase/sucrase ratio was 0.13. The infant
was considered to have CLD and has been well on a lac-
tose-free diet.
Case 3
A five-week-old Finnish boy was referred to the paediatric
outpatient clinic of Turku University Hospital because of
poor weight gain and failure-to-thrive. He was born at
term after an uneventful pregnancy as the second child of
healthy parents with a birth weight of 3810 g. He received
breast milk until two weeks of age, then he was put on a
regular, adapted, infant formula (Tutteli®, Valio Ltd, Fin-
land) but had poor weight gain and watery diarrhoea
from the first days of life. At the age of 5 weeks, his weight
was 150 grams below the birth weight though he ate rea-
sonably big amounts of infant formula (900 ml/d). He
showed metabolic acidosis (base excess was -12.3, pH
7.28, HCO3 14.9) and plasma sodium was high 165
mmol/l. In hospital, the values were corrected within aBMC Gastroenterology 2009, 9:8 http://www.biomedcentral.com/1471-230X/9/8
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day with iv infusions. His faecal elastase was found to be
normal, but his stools contained high amounts of reduc-
ing sugars. Because CLD was suspected, nutrition with lac-
tose-free whey-based, hydrolyzed formula (Pepti-Junior®,
Nutricia, Netherlands) was started. The diarrhoea ceased
during the first day and his weight gain improved remark-
ably. In specimen taken by gastroduodenoscopy, the mor-
phology of his upper gastrointestinal tract was normal,
but a very low activity of lactase was found in the duode-
nal specimen (because of the small size of the specimen,
the laboratory did not give any exact lactase value, but
they could not detect any activity) [11]. Later, at the age of
11 months lactose malabsorption was verified by a posi-
tive breath hydrogen test. Growth was normal on a lactose
free, whey-hydrolysate formula (Pepti-Junior). After the
age 12 of months he was put on a lactose-free regular milk
and he showed no gastrointestinal symptoms.
Case 4 and 5
Case 4, a four-day-old Dutch boy was admitted to the hos-
pital because of crying, irritability, a low grade fever and
refusing to eat starting a few hours earlier. He was born at
term to consanguineous parents (first cousins) of Turkish
origin after an uneventful pregnancy. He was breast-fed
and had yellow watery stools without blood or mucus
from birth. At presentation he was malnourished, dis-
tressed and irritated. His weight was 8% below birth
weight. He was suspected of having septicemia, but cul-
tures appeared to be negative. His plasma sodium was 152
mmol/l, base excess -12.8 mmol/l and faecal pH 5.4. Dis-
continuation of breastfeeding resulted in normalization
of stools within 18 hours. A carbohydrate free formula
was tolerated well; with addition of glucose to this feeding
he had normal stools, after adding lactose to the feeding
he again had several fluid stools and vomited. He was dis-
charged with a soy formula, on which he grew perfectly.
When he was 3 months and 10 months old duodenoscop-
ies were done; biopsies showed normal villi. At the age of
three months lactase activity was 1 U/g/protein (reference
values 2.8–6.7 U/wet weight). Activities of other disaccha-
ridases measured at the Erasmus Medical Centre Rotter-
dam [11] and alkaline phosphatase were normal (data
not shown). At the age of 10 months his lactase was < 1
U/g/protein (ref 38.5 ± 12.5), again with normal maltase
and sucrase activities (data not shown) (disaccharidase
activities were measured at the Academic Medical Centre
Amsterdam).
Case 5, the younger sister of case 4 was born at term after
an uneventful pregnancy. On day 3 after breastfeeding she
started to suffer from diarrhoea; on admission after some
hours her weight was 13% below birth weight. Soy for-
mula was started and her stools became more firm after
one week. She did very well on the soy formula. At age 11
months a duodenoscopy was performed, which showed
completely normal villi. Her lactase was 0 U/g/protein
(reference values 2.8–6.7 U/wet weight), with normal
activities of other disaccharidases (data not shown) (dis-
accharidase activities measured at the Academic Medical
Centre Amsterdam).
Control subjects
The control subjects were matched with the nationality of
the patients. Therefore, the control subjects consisted of
98 Finnish and 101 Italian control samples.
Ethics
The study protocol has been approved by the Ethics Com-
mittee of Helsinki University Hospital and performed in
accordance with the Declaration of Helsinki. The parents'
written informed consent was obtained.
PCR-sequencing
DNA was isolated from peripheral blood of the patients
and their parents and amplified by polymerase chain reac-
tion (PCR) covering the 17 exons and splice sites of the
LCT gene as described previously [10]. Primer sequences
are available on request from the authors. The size of the
PCR product was verified by 1.5% agarose gel electro-
phoresis with ethidium bromide. PCR products were puri-
fied using 2.5 U of Shrimp Alkaline Phosphatase (USB)
and 5 U of Exonuclease I (New England Biolabs) at 37°C
for 45 min and at 80°C for 15 min. For sequencing the
BigDye 3.1 terminator (Applied Biosystems) was used
according to the manufacturer's instructions. The
sequencing reaction was as follows: at 96°C for 1 min,
then 25 cycles at 96°C for 10 s, at 55°C for 5 s and at
60°C for 4 min. The sequencing reaction followed purifi-
cation by Millipore Multiscreen plates (Millipore, USA)
with Sephadex G-50 Superfine sepharose (Amersham Bio-
sciences, Sweden), electrophoresis by ABI 3730 DNA Ana-
lyzer (Applied Biosystems) and base calling by
Sequencing Analysis 5.2 software (Applied Biosystems).
The obtained sequence was analyzed using Sequencher
4.1.4 software (Gene Codes, USA).
Mutation prediction
The ClustalW alignment program was used to study con-
servation of the mutation sites among different species
[12]. To analyze the probability of specific amino acid
substitutions Blosum62 (BLOck SUbstitution Matrix)
scores were obtained [13]. The possible functional impact
of an amino acid change was predicted by the PolyPhen
(Polymorphism Phenotyping) program [14], which
makes predictions based on sequence annotation and
alignment as well as structural information, SIFT (Sorting
Intolerant From Tolerant) [15] and PANTHER PSEC [16]
that use sequence homology for prediction. SIFT gives a
prediction for whether the substitution is tolerated or notBMC Gastroenterology 2009, 9:8 http://www.biomedcentral.com/1471-230X/9/8
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and PATNTHER gives a substitution PSEC (position spe-
cific evolutionary conservation) score.
Results
Case 1
Two nucleotide substitutions in a heterozygous form in
the  LCT  gene were identified in the Italian patient:
c.2062T > C in exon 7 leading to a substitution of serine
to proline (S688P) and c.4834G > T in exon 12 leading to
glutamic acid to change to a premature stop codon
(E1612X) (Additional file 1). The mother of the patient
was shown to be a carrier of the mutation S688P and the
father a carrier of the mutation E1612X. No substitutions
were found in 101 Italian control subjects for E1612X and
97 for S688P suggesting that they are rare events. Using
ClustalW analysis, both mutations were located in the
conserved site (Figure 1). The Blosum62 score for substi-
tution from serine to proline is -1 (range from -4 to +11;
low to high probability of substitution) [17]. The effect of
mutation S688P was predicted to be possible damaging
by PolyPhen (position-specific independent counts; PSIC
score difference 1.773) (score > 1.7 considered damaging)
[18] and not tolerated by SIFT. From PANTHER PSEC
results could not be obtained.
Case 2
Deletion of five bases c.1692-1696delAGTGG in exon 6
leading to frameshift mutation V565fsX567 (Additional
file 1) was found in Finnish patient heterozygous for the
founder mutation Y1390X [10]. The deletion was located
in the conserved region of the LCT gene (Figure 1) and
was predicted to lead to truncated protein due to a change
in the reading frame. Unfortunately parental DNA was
not available for the analysis. The deletion was not found
in 98 anonymous Finnish blood donors.
Conservation of mutations sites Figure 1
Conservation of mutations sites. ClustalW alignment of human LPH protein and LPH proteins from other species showing 
the conservation of the region for mutations V565fsX567 (A), S688P (B), R1587H (C) and E1612X (C).BMC Gastroenterology 2009, 9:8 http://www.biomedcentral.com/1471-230X/9/8
Page 5 of 7
(page number not for citation purposes)
Case 3
The Finnish patient was first shown to be heterozygous for
the founder mutation Y1390X [10]. Sequencing of the
LCT  gene resulted in the identification of substitution
c.4760G→A in exon 12 which changes arginine to histi-
dine (R1587H) (Additional file 1). The mother was a car-
rier of the founder mutation and the father a carrier of the
novel substitution. The R1587H was not identified in 98
anonymous Finnish blood donors. Using the ClustalW
alignment program the amino acid was shown to be con-
served (Figure 1). The Blosum62 score for substitution
from arginine to histidine is 0. The effect of mutation
R1587H was predicted to be possible damaging by
PolyPhen (PSIC score difference 1.820) and not tolerated
by SIFT. The PANTHER subPSEC score was -4.41655 (cut
off point for deleterious mutation is < -3) [19].
Case 4 and 5
The previously known substitution c.4087G > A in exon 9
leading to an amino acid change from glycine to serine
(G1363S) (Additional file 1) was identified in a
homozygous form in both siblings. Both parents were
shown to be carriers of the same mutation.
Discussion
Here we report four new mutations in the LCT  gene
underlying congenital lactase deficiency (CLD). The
mutations were identified in compound heterozygous
form in three patients (Italian and Finnish) with charac-
teristic features of CLD. There are three kinds of evidence
that these mutations lead to CLD 1) the substitutions
change the amino acid sequence of a protein in a con-
served region of the LPH protein, 2) substitutions were
predicted to be damaging by several prediction methods
and 3) healthy control subjects lack these mutations. We
also found mutation G1363S in a homozygous form in
two siblings of Turkish origin. This mutation has earlier
been reported in one Finnish CLD patient in eastern (near
the Russian border) Finland suggesting that the mutation
may have been brought to Finland from the east [10]. This
is the first time that CLD cases and the underlying muta-
tions have been identified outside Finland.
Mutations E1612X and R1587H are located in the con-
served region IV of the mature LCT that encodes lactase
activity (Figure 2) [20-22]. Mutation E1612X leads to a
truncated protein. In substitution R1587H both amino
acids are polar, basic amino acids. However, arginine
always has a positive charge and a role in the maintenance
of protein overall charge balance. Therefore the substitu-
tion to histidine (which charge depends on environment)
may disturb the overall charge. Substitution S688P and
deletion V565fsX567 are located in the region II of the
pro-LPH that has been shown to have a role as an
intramolecular chaperone in the folding of the LPH-pro-
tein (Figure 2) [23,24]. Deletion V565fsX567 leads to
truncated protein after a few amino acids. A change from
a non-aromatic polar serine to cyclic and non-polar pro-
line causes a remarkable change in the chemical and phys-
ical properties of the protein.
Schematic presentation of the LCT gene and locations of the mutations Figure 2
Schematic presentation of the LCT gene and locations of the mutations. Cleavage sites are R734/L735 and R867/
A868.BMC Gastroenterology 2009, 9:8 http://www.biomedcentral.com/1471-230X/9/8
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All four novel mutations were examined by several predic-
tion programs [17]. Although the Blosum62 matrix does
not take into account the conservation of the protein
region, the results showed that there is low probability of
both substitutions (serine to proline and arginine to histi-
dine) of occurring in the functional protein. In PolyPhen
the prediction was based on PSIC score (logarithmic
ratios of likelihood of a studied amino acid occurring at a
particular site to the likelihood of same amino acid occur-
ring at any site) [18]. Since multiple alignment profile
scores provide a major contribution to the prediction, it
remains reasonably reliable even without the missing 3-D
information of LPH. [18]. Using PolyPhen both substitu-
tions (R1587H and S688P) were considered to be patho-
genic. The results obtained with SIFT or PANTHER PSEC
were in line with the results above.
Taken together, a total of nine mutations are known to
underlie CLD to date. The mutations are quite evenly dis-
tributed covering both the pro region and the mature LPH
(Figure 2). Location of mutations does not affect the
severity of the phenotype. In contrast, all mutations lead
to a severe phenotype. The phenotype of CLD is in striking
contrast with the phenotype of adult-type hypolactasia,
associated with the normal down-regulation of lactase
activity with mild or absent symptoms. It is noteworthy
that in these two conditions, the values of lactase activity
are partially overlapping in spite of their having different
underlying molecular mechanism [2,5-8,10]. However
symptoms are much more severe in CLD.
After the identification of the molecular background of
CLD, genetic testing has been offered in Finland. Interest-
ingly, nine novel CLD cases were identified in 2006 and
two in 2007. All patients were diagnosed at the first weeks
of age based on severe watery diarrhoea and loss of
weight. Nine of them were homozygous for the major
mutation Y1390X further confirming the original results
that only one major mutation is enriched in the Finnish
population [10]. Two patients were heterozygous for the
founder mutation. In both of them (case 2 and 3) new
mutations were reported here. Earlier, CLD has been esti-
mated to be very rare with a frequency of 1:60 000 new-
borns in Finland [5]. The figures presented here suggest
that CLD may be more common than previously esti-
mated. CLD should be suspected in neonates with severe
diarrhoea which starts after introduction of milk feeding.
A high concentration of lactose is present in liquid faeces
and may easily be identified. The diarrhoea is cured
within hours by substituting milk with a lactose-free for-
mula. Later, CLD may be diagnosed by either genetic test-
ing or by studying disaccharidase concentrations in the
duodenal mucosa.
Conclusion
Four new mutations that underlie CLD were identified, of
these, two are the first mutations found in continental
Europe. The location of mutation in LCT does not seem to
affect the severity of the disease. CLD seems to be more
common than previously assumed.
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